Project Grant R01HL184259
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $539K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Bloodworks $724,351 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate the mechanisms by which extracellular mitochondria released from traumatic brain injury sites cause endothelial cell injury and contribute to hemostatic dysfunction and coagulopathy. The research addresses a gap in understanding subcellular changes in endothelial cell injury during traumatic...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $391,700 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 15, 2026. The award funds mixed-methods health services research to optimize the regionalization of care for acute type A aortic dissection (ATAAD) and increase appropriate interfacility transfer of ATAAD patients from low-volume to high-volume aortic centers. The research...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $185,196 on January 7, 2027 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a pilot multi-center cohort study examining patient and caregiver burden in chronic limb-threatening ischemia (CLTI). Aim 1 will assess how caregiver support relates to patient outcomes including quality of life, amputation, readmission, and mortality, collecting...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $322,382 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating cell-specific interleukin-1 receptor 1 (IL-1R1) signaling in focal and diffuse traumatic brain injury models. The research uses genetically engineered mice with precise...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart Lung and Blood Institute awarded Brigham & Women's Hospital $1.702 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a small activating RNA (saRNA) therapeutic approach for treating atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis (MASH). The project restores macrophage efferocytosis—the clearance of dead cells—by reactivating the TIM4 receptor on macrophages using...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $686,610 in project grant funding on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation in atherosclerosis and evaluate therapeutic targeting of the MECOM transcription factor. The research will elucidate how MECOM drives endothelial inflammatory activation, examining mechanisms by which the protein enhances macrophage infiltration and...